A comparative study of tazobactam/piperacillin and piperacillin in chronic respiratory tract infections

Kotaro Oizumi, Masao Kawahara, Shinzo Kawaguchi, Hironari Sigematsu, Fumio Tanaka, Nobuhiko Sano, Akira Saito, Yohmei Hiraga, Mitsuhide Ohmichi, Hiroshi Inoue, Kazuki Konishi, Yoshiaki Mori, Akiko Shiba, Kenichi Takeuchi, Haruhito Hirano, Hitonobu Tomoike, Akira Suwabe, Kunio Shirato, Yasuo Tanno, Makoto TakahashiNoriko Onodera, Rika Yamaki, Kunio Kudo, Munehiko Ishii, Masahiro Sakamoto, Akira Watanabe, Toshihiro Nukiwa, Kazuo Sato, Kazunao Niizuma, Akira Ohishi, Kohtaro Kaneko, Kaoru Shimada, Shinichi Oka, Natsuo Tachikawa, Yasuyuki Sano, Yasuo Arai, Hiroyuki Kobayashi, Hidehiro Watanabe, Susumu Sakayori, Naohiko Chonabayashi, Koichiro Kudo, Hiroko Arioka, Harumi Shishido, Motoo Baba, Hisashi Watanabe, Masaru Koyama, Jingoro Shimada, Seiji Hori, Shoichiro Irimajiri, Yasuo Matsuoka, Mitsuo Obana, Takao Okubo, Hirotada Ikeda, Junichi Suzuki, Masanori Nishikawa, Tadamiki Miyazawa, Fumio Matsumoto, Takeo Imai, Shigeki Odagiri, Kaneo Suzuki, Kenichi Takahashi, Yasuhiro Yoshiike, Yoshihiro Hirai, Hidekazu Kitamura, Masaaki Arakawa, Kohichi Wada, Hiroki Tsukada, Nobuki Aoki, Osamu Sekine, Yasutoshi Suzuki, Saburo Izumi, Atsuhiko Sato, Kingo Chida, Kenzo Takagi, Ryujiro Suzuki, Toshihiko Takeuchi, Kazuo Yoshitomo, Toru Matsuura, Ikuji Usami, Fumiyuki Kuze, Katsuhiro Suzuki, Susumu Oguri, Akio Niimi, Yoshiro Mochizuki, Yasuharu Nakahara, Rieko Kanan, Kazushige Tsuyuguchi, Nakaaki Osawa, Kohka Min, Akitaka Iwagaki, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Kazuya Higashino, Takashi Nakano, Tetsuya Nishigaki, Rinzo Soejima, Yoshihito Niki, Osamu Moriya, Masamitsu Nakashima, Toshiharu Matsushima, Makoto Kimura, Michio Yamakido, Kenji Hasegawa, Takao Sasaki, Yuji Sugimoto, Masahide Takii, Yuji Kawarada, Katsuhiko Furuumi, Tsuneo Ishibashi, Masahiro Takamoto, Yasuko Harada, Akira Kajiki, Kohei Hara, Toshiyuki Ohe, Junji Ohi, Masao Nakatomi, Kiyo Fujita, Miyako Ishiguro, Tatsuya Katsumata, Hideaki Sawa, Keizo Matsumoto, Tsuyoshi Nagatake, Naoto Rikitomi, Hironori Masaki, Tasuku Sakamoto, Hiroyuki Yoshimine, Reiki Kuroki, Motoo Baba, Keiko Tsuchihashi, Hirofumi Tanaka, Mikio Taguchi, Hidehiko Hirose, Hiroshi Watanabe, Masakazu Takasugi, Masayuki Ando, Moritaka Suga, Naoki Saita, Kiyoshi Shima, Shinobu Takenaka, Fujio Tanaka, Masaru Nasu, Tohru Yamasaki, Jun Goto, Kazuo Kitagawa, Atsushi Saito, Hiroshi Fukuhara, Futoshi Hiki, Jun Inadome, Nobuya Ogawa, Koichi Deguchi

    研究成果: Article査読

    2 被引用数 (Scopus)

    抄録

    The efficacy, safety and usefulness were evaluated for a combined antibiotic tazobactam/piperacillin (TAZ/PIPC) consisting of a new β-lactamase inhibitor, tazobactam (TAZ), and a broad spectrum penicillin antibiotic, piperacillin (PIPC), in chronic respiratory tract infections with PIPC as the control in a multi-institutional comparative study. The drugs used were a preparation containing 0.5 g of TAZ and 2.0 g of PIPC per vial (TAZ/PIPC group) and a preparation containing 2.0 g of (PIPC group). The drugs were intravenously injected one vial at a time twice a day for 14 days as a rule. The following results were obtained: 1. Clinical effect There was no significant difference between TAZ/PIPC (86% or 76/88) and PIPC (81% or 69/85). 2. Bacteriological effect There was no significant difference between TAZ/PIPC (93% or 42/45) and PIPC (88% or 36/41) in terms of bacterial eradication rates. In 34 patients with β-lactamase-producing pyogenic bacteria, there was no significant difference between TAZ/PIPC (77% or 10/13) and PIPC (88% or 15/17). 3. Degrees of improvement in clinical symptoms, signs and laboratory findings The TAZ/PIPC group was likely to show reductions in fever and the amount of sputum soon after administration. 4. Side effects Incidences of side effects were 7% (7/96) in the TAZ/PIPC group and 3% (3/89) in the PIPC group, showing no significant difference between the two groups. The main symptoms were allergic reaction and gastrointestinal symptoms. 5. Abnormal clinical laboratory test values The incidence was 17% (15/89) in the TAZ/PIPC group and 21% (18/87) in the PIPC group. The main symptoms were eosinophilia and hepatic dysfunction, and most of these symptoms were mild. 6. Usefulness The usefulness rates in the TAZ/PIPC group were 80% (71/89) and 78% (66/85) in the PIPC group, showing no significant difference. Thus, TAZ/PIPC exhibited excellent clinical effects and presented no troubles with safety. When comprehensively evaluated, TAZ/PIPC appears to be a very useful drug for the treatment of chronic respiratory tract infections.

    本文言語English
    ページ(範囲)482-513
    ページ数32
    ジャーナルThe Japanese Journal of Antibiotics
    48
    4
    DOI
    出版ステータスPublished - 1995 4

    ASJC Scopus subject areas

    • Microbiology (medical)
    • Pharmacology (medical)
    • Infectious Diseases

    フィンガープリント 「A comparative study of tazobactam/piperacillin and piperacillin in chronic respiratory tract infections」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

    引用スタイル